Management of hypertension in patients with left ventricular hypertrophy. 2007

Cesare Cuspidi, and Carla Sala, and Alberto Zanchetti
Policlinico di Monza, Via Amati 111, 20052 Monza, Italy. cesare.cuspidi@unimib.it

Left ventricular hypertrophy (LVH) is a cardinal manifestation of organ damage in patients with arterial hypertension. Identifying LVH is a fundamental step in evaluating hypertensive patients, because clinical and epidemiologic studies have shown this condition has a strong independent adverse prognostic significance. LVH is an integrated marker of cardiovascular risk, reflecting hypertension's hemodynamic and nonhemodynamic effects on the heart. Reversing LVH is an intermediate goal of antihypertensive therapy. Pharmacologic strategies to reverse LVH should be based on combining two or more drugs: a renin-angiotensin system blocker (ie, angiotensin-converting enzyme inhibitor or angiotensin receptor antagonist), and a calcium antagonist or low-dose diuretic. Successful therapeutic plans should also include nonpharmacologic interventions to promote LVH regression.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000959 Antihypertensive Agents Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. Anti-Hypertensive,Anti-Hypertensive Agent,Anti-Hypertensive Drug,Antihypertensive,Antihypertensive Agent,Antihypertensive Drug,Anti-Hypertensive Agents,Anti-Hypertensive Drugs,Anti-Hypertensives,Antihypertensive Drugs,Antihypertensives,Agent, Anti-Hypertensive,Agent, Antihypertensive,Agents, Anti-Hypertensive,Agents, Antihypertensive,Anti Hypertensive,Anti Hypertensive Agent,Anti Hypertensive Agents,Anti Hypertensive Drug,Anti Hypertensive Drugs,Anti Hypertensives,Drug, Anti-Hypertensive,Drug, Antihypertensive,Drugs, Anti-Hypertensive,Drugs, Antihypertensive
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D015995 Prevalence The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time. Period Prevalence,Point Prevalence,Period Prevalences,Point Prevalences,Prevalence, Period,Prevalence, Point,Prevalences
D017379 Hypertrophy, Left Ventricular Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality. Left Ventricular Hypertrophy,Ventricular Hypertrophy, Left,Hypertrophies, Left Ventricular,Left Ventricular Hypertrophies,Ventricular Hypertrophies, Left
D018450 Disease Progression The worsening and general progression of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis. Clinical Course,Clinical Progression,Disease Exacerbation,Exacerbation, Disease,Progression, Clinical,Progression, Disease

Related Publications

Cesare Cuspidi, and Carla Sala, and Alberto Zanchetti
January 1995, Likars'ka sprava,
Cesare Cuspidi, and Carla Sala, and Alberto Zanchetti
December 1990, Archives des maladies du coeur et des vaisseaux,
Cesare Cuspidi, and Carla Sala, and Alberto Zanchetti
October 1990, Journal of human hypertension,
Cesare Cuspidi, and Carla Sala, and Alberto Zanchetti
March 2004, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
Cesare Cuspidi, and Carla Sala, and Alberto Zanchetti
February 1995, Archives des maladies du coeur et des vaisseaux,
Cesare Cuspidi, and Carla Sala, and Alberto Zanchetti
August 1987, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
Cesare Cuspidi, and Carla Sala, and Alberto Zanchetti
January 1994, Likars'ka sprava,
Cesare Cuspidi, and Carla Sala, and Alberto Zanchetti
October 2002, Presse medicale (Paris, France : 1983),
Cesare Cuspidi, and Carla Sala, and Alberto Zanchetti
March 1989, Clinical cardiology,
Cesare Cuspidi, and Carla Sala, and Alberto Zanchetti
December 1985, The Kobe journal of medical sciences,
Copied contents to your clipboard!